Takeda Pharmaceutical Company Limited
) and partner, Zinfandel Pharmaceuticals, Inc. recently initiated
a phase III study (TOMMORROW) on pioglitazone. The study is
evaluating a genetic-based biomarker risk assignment algorithm
(risk assignment algorithm) to detect the risk of mild cognitive
impairment (MCI) due to Alzheimer's disease (AD) within five
ACTELION LTD (ALIOF): Get Free Report
NOVARTIS AG-ADR (NVS): Free Stock Analysis
PFIZER INC (PFE): Free Stock Analysis Report
TAKEDA PHARMACT (TKPYY): Get Free Report
To read this article on Zacks.com click here.
Takeda and Zinfandel are also evaluating the efficacy of
pioglitazone in delaying patients from being affected by MCI due
to AD. It is evaluating cognitively normal individuals at high
risk as determined by the risk assignment algorithm. The
algorithm consists of apolipoprotein E (APOE) and TOMM40
genotypes and age. Age and APOE genotype have been earlier proved
to elevate the risk of AD.
Takeda mentioned in its press release that the World Alzheimer
Report 2010 estimated that dementia in some form or the other
affected 35.6 million people across the globe. The incidence of
the disease is on the rise and the report indicated that the
disease is expected to affect 65.7 million and 115.4 million
people globally by 2030 and 2050 respectively. AD is also highly
prevalent in the U.S.
We remind investors that the Alzheimer's disease market is
currently extremely competitive with the presence of companies
). Several other companies are also looking to enter the market.
Earlier this month, Takeda and partner, Dainippon Sumitomo Pharma
Co., Ltd. announced the approval of their atypical antipsychotic
medication, Latuda, in Switzerland. Approval was granted for
treating patients suffering from schizophrenia. Latuda was
approved in the U.S. for the treatment of schizophrenia in Oct
2010 and for major depressive episodes associated with bipolar I
disorder in Jun 2013.
Takeda carries a Zacks Rank #3 (Hold). Currently, companies like
) look well positioned in the pharma space with a Zacks Rank #1